Abstract
Cultured rat astrocytes and C6 rat glioma were used as a differential screen for a variety of 1,2,3,4-tetrahydroisoquinoline (THI) derivatives. Compound 1 [1-(biphenyl-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol hydrochloride] selectively blocked the growth of C6 glioma leaving normal astrocytes relatively unaffected. The potential for clinical utility of 1 was further substantiated in human gliomas and other tumor cell lines. Preliminary SAR of this activity was characterized by synthesis and testing of several THI and conformationally flexible variants.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Astrocytes / drug effects
-
Biphenyl Compounds / chemical synthesis*
-
Biphenyl Compounds / chemistry
-
Biphenyl Compounds / pharmacology
-
Cell Line, Tumor
-
Cells, Cultured
-
Drug Screening Assays, Antitumor
-
Glioma
-
Humans
-
Isoquinolines / chemical synthesis*
-
Isoquinolines / chemistry
-
Isoquinolines / pharmacology
-
Molecular Conformation
-
Rats
-
Structure-Activity Relationship
-
Tetrahydroisoquinolines / chemical synthesis*
-
Tetrahydroisoquinolines / chemistry
-
Tetrahydroisoquinolines / pharmacology
Substances
-
1-(biphenyl-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol
-
Antineoplastic Agents
-
Biphenyl Compounds
-
Isoquinolines
-
Tetrahydroisoquinolines